#406 ‒ Migraine, cluster headache, and tension headache: symptoms, causes, prevention, and treatment | Brian Grosberg, M.D.

What It Covers

Peter Attia interviews headache specialist Dr. Brian Grosberg, director of the Hartford HealthCare Headache Program, covering the classification, pathophysiology, and treatment of migraine, cluster, and tension headaches. Migraine affects 12% of the population globally — roughly one billion people — with women impacted three times more often than men, yet the condition remains chronically underdiagnosed and undertreated.

Key Questions Answered

• •Migraine diagnosis without biomarkers: No MRI or blood test confirms migraine. Diagnosis relies entirely on clinical criteria: at least five lifetime attacks lasting 4–72 hours, with two of four features — unilateral pain, pulsating quality, moderate-to-severe intensity, and avoidance of activity — plus nausea or light and sound sensitivity. Up to 40% of migraine sufferers have bilateral pain, a commonly unknown fact that leads to frequent misdiagnosis as tension headache or sinus headache.
• •Headache diary as primary diagnostic tool: Keeping a month-view headache diary is the single most actionable step for any headache sufferer. It captures timing relative to menstrual cycles, caffeine intake, sleep schedule, stress, and food — patterns invisible without systematic tracking. Grosberg uses 15-page intake questionnaires and diary data to identify triggers, confirm diagnosis, and design individualized treatment plans. His downloadable diary is available on his clinic website.
• •Obesity multiplies migraine risk fivefold: Morbid obesity (BMI 35+) increases chronic migraine risk by 5x; standard obesity (BMI 30–35) doubles it. Weight loss — both surgical and nonsurgical — demonstrably reduces migraine frequency. This risk is independent of other pain disorders. For migraine sufferers carrying excess weight, addressing obesity is a high-leverage intervention that simultaneously reduces cardiovascular and cancer risk, joint wear, and headache burden.
• •Estrogen decline rate drives menstrual migraine: Two-thirds of women with migraine experience perimenstrual attacks. The trigger is not low estrogen per se, but the *rate* of estrogen decline in the late luteal phase — women with migraine experience a faster drop than non-sufferers. This mechanism, identified in studies from the 1970s onward, explains why pure menstrual migraine (attacks only around menses, under 10% of women) and menstrual-related migraine (50% of women) cluster in the days just before and during menstruation.
• •CGRP-targeted therapies are the biggest treatment advance: Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) — administered as monthly self-injections or quarterly infusions — produce meaningful improvement in roughly 60% of migraine patients. Failing one drug in this class does not predict failure of another, since each antibody binds a different epitope. Oral small-molecule CGRP antagonists (gepants) like atogepant serve as preventive therapy; rimegepant carries both acute and preventive FDA approval.
• •Medication overuse is a hidden chronification driver: Using NSAIDs, acetaminophen, or triptans two or more days per week regularly can paradoxically increase headache frequency — a phenomenon called medication overuse headache. Opioids and barbiturate-containing analgesics like Fioricet carry the highest risk and can trigger this effect even when used only a handful of times per month. Grosberg treats opioids as an absolute last resort and avoids them even in emergency room settings.
• •Cluster headache requires urgent specialist access: Cluster headache — nicknamed "suicide headache" — produces attacks peaking within 5–15 minutes, lasting up to 3 hours, occurring up to 8 times daily, with 97% of patients showing ipsilateral eyelid droop, eye redness, and nasal congestion. Circadian and circannual periodicity (driven by hypothalamic and pineal involvement) means attacks cluster in January–February and July–August. Daylight saving time changes reliably trigger flares. Nearly all cluster patients require both acute and preventive pharmacologic treatment simultaneously.